Table 1 Descriptive statistics
Clinical variables | |
Participants, number | 841 |
Demographic characteristics | |
Age (841 participants), median (range) | 60 years (21–90) |
Female gender (841 participants), n (%) | 691 (82.2%) |
RA-related features | |
RF and/or ACPA (841 participants), n (%) | 615 (73.1%) |
Disease duration (834 participants), median (range) | 8.2 years (0.1–35) |
Extra-articular features (840 participants), n (%) | 138 (16.4%) |
Radiographic damage (814 participants), n (%) | 383 (47.1%) |
Joint surgery (841 participants), n (%) | 101 (12.4%) |
Maintenance of remission (836 participants), n (%) | 349 (41.8%) |
CRP (833 participants), mean ± SD | 4.31 ± 3.62 mg/L |
Traditional CV risk factors | |
BMI (829 participants), mean ± SD | 27.01 ± 4.02 |
HBP (811 participants), n (%) | 400 (49.3%) |
High cholesterol (798 participants), n (%) | 256 (32.1%) |
Smoking habit (836 participants), n (%) | 264 (31.6%) |
MetS (807 participants), n (%) | 180 (22.3%) |
T2D (811 participants), n (%) | 98 (12.1%) |
Therapies | |
ASA (838 participants), n (%) | 320 (38.2%) |
CCS (841 participants), n (%) | 612 (72.8%) |
CCSs low dosage (841 participants), n (%) | 504 (60.0%) |
MTX (841 participants), n (%) | 716 (85.1%) |
HCQ (813 participants), n (%) | 231 (28.5%) |
LEF (841 participants), n (%) | 186 (22.1%) |
SSZ (841 participants), n (%) | 113 (13.4%) |
Biologic DMARDs (841 participants), n (%) | 517 (61.5%) |
TNFi (841 participants), n (%) | 308 (36.6%) |
Non TNFi (841 participants), n (%) | 209 (24.9%) |